Polypharmacy, declined walking speed, bent back, and disability associated with a history of falls in Japanese patients with rheumatoid arthritis: Results from the IORRA cohort study

Click to increase image sizeClick to decrease image size

Conflict of interest

T.F. has served on speakers’ bureaus for Ayumi Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corporation, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Ono Pharmaceutical Co., Ltd., Pfizer Japan Inc., and Taisho Pharmaceutical Co., Ltd. E.I. has received speaker's fees from Bristol-Myers Squibb and Pfizer Japan, Inc. E.T. has received lecture fees or consulting fees from AbbVie, Asahi Kasei Pharma Co., Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo Co., Eisai Pharmaceutical, Janssen Pharmaceutical K.K., Nippon Kayaku, Pfizer, Takeda Pharmaceutical, Taisho Toyama Pharmaceutical Co., and UCB Pharma.

K.I. has received speaker’s fees from Asahi Kasei Pharma Corp., Astellas Pharma Inc., AbbVie Japan GK, Ayumi Pharmaceutical Co., Bristol-Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Kaken Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corp., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., Teijin Pharma, Ltd., and UCB Japan Co., Ltd. H.Y. has received a research grant from and has served on speakers’ bureaus for AbbVie, Astellas, Ayumi, Behringer, Bristol-Meyers, Chugai, Daiichi-Sankyo, Eisai, Kaken, Nippon-Shinyaku, Novartis, Ono, Pfizer, Taisyo-Toyama, Takeda, Tanabe-Mitsubishi, Teijin Pharma, Torii, UCB, and YLbio. M.H. has received research grants from AbbVie Japan GK, Asahi Kasei Corp., Astellas Pharma, Inc., Ayumi Pharmaceutical Co., Bristol-Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Daiichi-Sankyo, Inc., Eisai Co., Ltd., Kissei Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Co., Nippon Kayaku Co., Ltd., Sekisui Medical, Shionogi & Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma, Ltd. M.H. has received speaker’s fees from AbbVie Japan GK, Ayumi Pharmaceutical Co., Boehringer Ingelheim Japan, Inc., Bristol-Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Kissei Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., and Teijin Pharma Ltd. M.H. is also a consultant for AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb Co., Kissei Pharmaceutical Co., Ltd. and Teijin Pharma.

Acknowledgments

We thank all members of the Institute of Rheumatology, Tokyo Women’s Medical University for the successful management of the IORRA cohort.